New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients.
Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science (New York, N.Y.) Mathew, D., Marmarelis, M. E., Foley, C., Bauml, J. M., Ye, D., Ghinnagow, R., Ngiow, S. F., Klapholz, M., Jun, S., Zhang, Z., Zorc, R., Davis, C. W., Diehn, M., Giles, J. R., Huang, A. C., Hwang, W. T., Zhang, N. R., Schoenfeld, A. J., Carpenter, E. L., Langer, C. J., Wherry, E. J., Minn, A. J. 2024; 384 (6702): eadf1329Abstract
Persistent inflammation driven by cytokines such as type-one interferon (IFN-I) can cause immunosuppression. We show that administration of the Janus kinase 1 (JAK1) inhibitor itacitinib after anti-PD-1 (programmed cell death protein 1) immunotherapy improves immune function and antitumor responses in mice and results in high response rates (67%) in a phase 2 clinical trial for metastatic non-small cell lung cancer. Patients who failed to respond to initial anti-PD-1 immunotherapy but responded after addition of itacitinib had multiple features of poor immune function to anti-PD-1 alone that improved after JAK inhibition. Itacitinib promoted CD8 T cell plasticity and therapeutic responses of exhausted and effector memory-like T cell clonotypes. Patients with persistent inflammation refractory to itacitinib showed progressive CD8 T cell terminal differentiation and progressive disease. Thus, JAK inhibition may improve the efficacy of anti-PD-1 immunotherapy by pivoting T cell differentiation dynamics.
View details for DOI 10.1126/science.adf1329
View details for PubMedID 38900877